以宫颈癌为靶点的 M1 巨噬细胞膜包裹紫杉醇/β-榄香烯纳米粒子用于强化治疗

IF 5.2 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Yi Wang , Jiakun Wang , Chengbo Huang , Yang Ding , Leyao Lv , Yuhao Zhu , Nuo Chen , Yingyi Zhao , Qing Yao , Shengjie Zhou , Mei Chen , Qibing Zhu , Lifeng Li , Fengyun Chen
{"title":"以宫颈癌为靶点的 M1 巨噬细胞膜包裹紫杉醇/β-榄香烯纳米粒子用于强化治疗","authors":"Yi Wang ,&nbsp;Jiakun Wang ,&nbsp;Chengbo Huang ,&nbsp;Yang Ding ,&nbsp;Leyao Lv ,&nbsp;Yuhao Zhu ,&nbsp;Nuo Chen ,&nbsp;Yingyi Zhao ,&nbsp;Qing Yao ,&nbsp;Shengjie Zhou ,&nbsp;Mei Chen ,&nbsp;Qibing Zhu ,&nbsp;Lifeng Li ,&nbsp;Fengyun Chen","doi":"10.1016/j.ijpx.2024.100276","DOIUrl":null,"url":null,"abstract":"<div><p>Cervical cancer is a leading cause of cancer-related mortality in females worldwide, necessitating urgent solutions for effective treatment. Paclitaxel (PTX), a natural diterpene alkaloid compound, has the ability to inhibit mitosis and induce programmed apoptosis in tumor cells. However, its toxicity and drug resistance limit its efficacy in certain cervical cancer patients. β-elemene (β-ELE) can reverse multidrug resistance by inhibiting ATP-binding cassette transporters, thereby enhancing chemotherapy drug retention. Therefore, we propose a combination therapy using PTX/β-ELE to improve chemotherapy sensitivity. To enhance targeted drug delivery, we developed M1-macrophage-membrane-coated nanoparticles (M1@PLGA/PTX/β-ELE) for co-delivery of PTX&amp;β-ELE. Through both <em>in vitro</em> and <em>in vivo</em> cervical cancer models, we demonstrated that M1@PLGA/PTX/β-ELE effectively suppressed tumor progression and polarization of tumor-associated macrophages. Furthermore, H&amp;E staining confirmed the high therapeutic biosafety of M1@PLGA/PTX/β-ELE as there was no significant damage observed in major organs throughout the entire therapeutic process. Overall, this study presents a targeted biomimetic nanoplatform and combinatorial strategy that synergistically enhances chemosensitivity in malignant tumors.</p></div>","PeriodicalId":14280,"journal":{"name":"International Journal of Pharmaceutics: X","volume":"8 ","pages":"Article 100276"},"PeriodicalIF":5.2000,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590156724000483/pdfft?md5=428acdc9d41659fed71ace04dce58008&pid=1-s2.0-S2590156724000483-main.pdf","citationCount":"0","resultStr":"{\"title\":\"M1 macrophage-membrane-cloaked paclitaxel/β-elemene nanoparticles targeting cervical cancer for enhanced therapy\",\"authors\":\"Yi Wang ,&nbsp;Jiakun Wang ,&nbsp;Chengbo Huang ,&nbsp;Yang Ding ,&nbsp;Leyao Lv ,&nbsp;Yuhao Zhu ,&nbsp;Nuo Chen ,&nbsp;Yingyi Zhao ,&nbsp;Qing Yao ,&nbsp;Shengjie Zhou ,&nbsp;Mei Chen ,&nbsp;Qibing Zhu ,&nbsp;Lifeng Li ,&nbsp;Fengyun Chen\",\"doi\":\"10.1016/j.ijpx.2024.100276\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Cervical cancer is a leading cause of cancer-related mortality in females worldwide, necessitating urgent solutions for effective treatment. Paclitaxel (PTX), a natural diterpene alkaloid compound, has the ability to inhibit mitosis and induce programmed apoptosis in tumor cells. However, its toxicity and drug resistance limit its efficacy in certain cervical cancer patients. β-elemene (β-ELE) can reverse multidrug resistance by inhibiting ATP-binding cassette transporters, thereby enhancing chemotherapy drug retention. Therefore, we propose a combination therapy using PTX/β-ELE to improve chemotherapy sensitivity. To enhance targeted drug delivery, we developed M1-macrophage-membrane-coated nanoparticles (M1@PLGA/PTX/β-ELE) for co-delivery of PTX&amp;β-ELE. Through both <em>in vitro</em> and <em>in vivo</em> cervical cancer models, we demonstrated that M1@PLGA/PTX/β-ELE effectively suppressed tumor progression and polarization of tumor-associated macrophages. Furthermore, H&amp;E staining confirmed the high therapeutic biosafety of M1@PLGA/PTX/β-ELE as there was no significant damage observed in major organs throughout the entire therapeutic process. Overall, this study presents a targeted biomimetic nanoplatform and combinatorial strategy that synergistically enhances chemosensitivity in malignant tumors.</p></div>\",\"PeriodicalId\":14280,\"journal\":{\"name\":\"International Journal of Pharmaceutics: X\",\"volume\":\"8 \",\"pages\":\"Article 100276\"},\"PeriodicalIF\":5.2000,\"publicationDate\":\"2024-08-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2590156724000483/pdfft?md5=428acdc9d41659fed71ace04dce58008&pid=1-s2.0-S2590156724000483-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Pharmaceutics: X\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590156724000483\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pharmaceutics: X","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590156724000483","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

宫颈癌是全球女性因癌症死亡的主要原因之一,因此迫切需要有效的治疗方案。紫杉醇(PTX)是一种天然二萜生物碱化合物,具有抑制有丝分裂和诱导肿瘤细胞程序性凋亡的作用。然而,其毒性和耐药性限制了它对某些宫颈癌患者的疗效。β-榄香烯(β-ELE)可通过抑制 ATP 结合盒转运体逆转多药耐药性,从而提高化疗药物的保留率。因此,我们建议使用 PTX/β-ELE 联合疗法来提高化疗敏感性。为了加强靶向给药,我们开发了M1-巨噬细胞-膜包被纳米颗粒(M1@PLGA/PTX/β-ELE),用于联合给药PTX&β-ELE。通过体外和体内宫颈癌模型,我们证实 M1@PLGA/PTX/β-ELE 能有效抑制肿瘤进展和肿瘤相关巨噬细胞的极化。此外,H&E染色证实了M1@PLGA/PTX/β-ELE的高度治疗生物安全性,因为在整个治疗过程中未观察到主要器官的明显损伤。总之,本研究提出了一种靶向仿生纳米平台和组合策略,可协同增强恶性肿瘤的化疗敏感性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

M1 macrophage-membrane-cloaked paclitaxel/β-elemene nanoparticles targeting cervical cancer for enhanced therapy

M1 macrophage-membrane-cloaked paclitaxel/β-elemene nanoparticles targeting cervical cancer for enhanced therapy

Cervical cancer is a leading cause of cancer-related mortality in females worldwide, necessitating urgent solutions for effective treatment. Paclitaxel (PTX), a natural diterpene alkaloid compound, has the ability to inhibit mitosis and induce programmed apoptosis in tumor cells. However, its toxicity and drug resistance limit its efficacy in certain cervical cancer patients. β-elemene (β-ELE) can reverse multidrug resistance by inhibiting ATP-binding cassette transporters, thereby enhancing chemotherapy drug retention. Therefore, we propose a combination therapy using PTX/β-ELE to improve chemotherapy sensitivity. To enhance targeted drug delivery, we developed M1-macrophage-membrane-coated nanoparticles (M1@PLGA/PTX/β-ELE) for co-delivery of PTX&β-ELE. Through both in vitro and in vivo cervical cancer models, we demonstrated that M1@PLGA/PTX/β-ELE effectively suppressed tumor progression and polarization of tumor-associated macrophages. Furthermore, H&E staining confirmed the high therapeutic biosafety of M1@PLGA/PTX/β-ELE as there was no significant damage observed in major organs throughout the entire therapeutic process. Overall, this study presents a targeted biomimetic nanoplatform and combinatorial strategy that synergistically enhances chemosensitivity in malignant tumors.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
International Journal of Pharmaceutics: X
International Journal of Pharmaceutics: X Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
6.60
自引率
0.00%
发文量
32
审稿时长
24 days
期刊介绍: International Journal of Pharmaceutics: X offers authors with high-quality research who want to publish in a gold open access journal the opportunity to make their work immediately, permanently, and freely accessible. International Journal of Pharmaceutics: X authors will pay an article publishing charge (APC), have a choice of license options, and retain copyright. Please check the APC here. The journal is indexed in SCOPUS, PUBMED, PMC and DOAJ. The International Journal of Pharmaceutics is the second most cited journal in the "Pharmacy & Pharmacology" category out of 358 journals, being the true home for pharmaceutical scientists concerned with the physical, chemical and biological properties of devices and delivery systems for drugs, vaccines and biologicals, including their design, manufacture and evaluation. This includes evaluation of the properties of drugs, excipients such as surfactants and polymers and novel materials. The journal has special sections on pharmaceutical nanotechnology and personalized medicines, and publishes research papers, reviews, commentaries and letters to the editor as well as special issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信